Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...
Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech ...
In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally ...
The second time is not the charm for Replimune’s melanoma candidate RP1. | The second time is not the charm for Replimune’s ...
In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
Artificial intelligence has long been seen as a way to supercharge drug development. | Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of ...
A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...
Philips has issued a voluntary recall of software for its Trilogy Evo ventilator ser | Philips issued a voluntary recall of ...
Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...
Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...
Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results